The public offerings by immuno-oncology-focused Forty Seven Inc., which is developing anti-CD47 antibodies against a number of cancers, and Jerusalem-based Entera Bio Ltd. Thursday brought the number of biopharma companies graduating to the U.S. public ranks to 14 this month. According to BioWorld's public financings database, you have to travel back to August 2000 for a higher monthly total when 17 companies went public.